Pembrolizumab and Cabozantinib in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma (RMHNSCC): 2-year Long Term Survival Update with Biomarker Analysis
Nabil F. Saba(Emory University), Christine H. Chung(Moffitt Cancer Center), Dong M. Shin(Emory University), Kedar Kirtane(Moffitt Cancer Center), Asari Ekpenyong(Emory University), Xiaofei Song(Moffitt Cancer Center), Nicole C. Schmitt(Emory University), Ritu Chaudhary(Moffitt Cancer Center), Soumon Rudra(Emory University), Conor Steuer(Emory University), Yan Liu(Southwest Medical University), Yuhang Teng(Emory University), Johann Gross(Emory University), Maciej Biernacki(Moffitt Cancer Center), Robbert J.C. Slebos(University of Iowa), Ashley McCook(Emory University), William Stokes(Emory University)
International Journal of Radiation Oncology*Biology*Physics
March 14, 2024
Cited by 0
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Proteogenomic characterization of human colon and rectal cancer
|Nature|2014|1.6k
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
|New England Journal of Medicine|2008|1.5k